Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
14.29
+0.41 (2.95%)
At close: Jan 21, 2025, 4:00 PM
14.30
+0.01 (0.07%)
After-hours: Jan 21, 2025, 7:30 PM EST
Zymeworks Revenue
Zymeworks had revenue of $16.00M in the quarter ending September 30, 2024, a decrease of -3.07%. This brings the company's revenue in the last twelve months to $62.20M, down -86.52% year-over-year. In the year 2023, Zymeworks had annual revenue of $76.01M, down -81.57%.
Revenue (ttm)
$62.20M
Revenue Growth
-86.52%
P/S Ratio
17.21
Revenue / Employee
$223,737
Employees
278
Market Cap
984.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ZYME News
- 13 days ago - Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 - GlobeNewsWire
- 4 weeks ago - Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule - Seeking Alpha
- 2 months ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - GlobeNewsWire
- 2 months ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab - Seeking Alpha
- 2 months ago - Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewsWire